S.I. No. 353/2025 - Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2025 Skip to content Disclaimer Feedback Helpdesk Gaeilge Léim go dtí an t-ábhar Séanadh Aiseolas Deasc chabhrach English Gaeilge English Produced by the Office of the Attorney General Táirgthe ag Oifig an Ard-Aighne Home Legislation Acts of the Oireachtas Statutory Instruments Pre-1922 Legislation Constitution External Resources Bills (Houses of the Oireachtas) Iris Oifigiúil / Official Gazette Revised Acts (LRC) Classified List of Legislation (LRC) Translations (acts.
- ie)Translations (Houses of the Oireachtas) Government Publications for Sale EU Law (EUR-Lex) FAQ Disclaimer Feedback Helpdesk Search Baile Reachtaíocht Achtanna an Oireachtais Ionstraimí Reachtúla Reachtaíocht Réamh-1922 Bunreacht Acmhainní Seachtracha Billí (Tithe an Oireachtais) Iris Oifigiúil Achtanna Athbhreithnithe (CAD) (An Coimisiún um Athchóiriú an Dlí) Liosta Rangaithe Reachtaíochta Aistriúcháin (achtanna.
- ie)Aistriúcháin (Tithe an Oireachtais) Foilseacháin Rialtais ar Díol Dlí AE (EUR-Lex) CCanna (Ceisteanna Coitianta) Séanadh Aiseolas Deasc chabhrach Cuardach TitleTeideal Year(
- s)or rangeBliain nó blianta nó raon TypeCineál All Legislation Acts Statutory Instruments Advanced SearchCuardach Casta HomeBaile Statutory InstrumentsIonstraimí Reachtúla 2025 S.I. No. 353/2025 - Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2025 S.I. No. 353/2025 - Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2025 AmendmentsLeasuithe Download PDF Íoslódáil PDF Notice of the making of this Statutory Instrument was published in “Iris Oifigiúil” of 25th July, 2025. I, JENNIFER CARROLL MACNEILL, Minister for Health, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006) and section 9 of the Irish Medicines Board (Miscellaneous Provisions) Act 2024 (No. 4 of 2024)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations: 1.
(1)These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations 2025.
(2)The collective citation “the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2025” includes these Regulations.
- In these Regulations – “Principal Regulations” means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 ( S.I. No. 540 of 2003 ); “Regulations of 2024” means the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024 ( S.I. No. 582 of 2024 ). The Twelfth Schedule (as amended by Regulation 3 of the Regulations of 2024) to the Principal Regulations is amended by inserting the following entry: “ Medicinal product Form and presentation of product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration Column 1 Column 2 Column 3 Column 4 Column 5 Nirsevimab 50mg in 0.5mL pre-filled syringe; 100mg in 1mL pre-filled syringe. Intramuscular (IM) injection. Passive immunisation with nirsevimab of all infants who are born during the RSV season. Passive immunisation with nirsevimab of all *high-risk infants aged ≤12 months at the start of their first RSV season. Passive immunisation with nirsevimab of all infants who are aged ≤6 months at the start of the RSV season. Passive immunisation with nirsevimab of all ex-preterm infants under 24 months of age with Chronic Lung Disease in their second RSV season. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Infants weight<5kg: A single dose of 50mg (0.5ml) administered intramuscularly. Infants weight≥5kg: A single dose of 100mg (1.0ml) administered intramuscularly. Children up to 24 months entering their second season: 200 mg given as 2 × 100 mg intramuscular injections. ”. GIVEN under my Official Seal, 22 July,
- JENNIFER CARROLL MACNEILL, Minister for Health. EXPLANATORY NOTE (This note is not part of the Instrument and does not purport to be a legal interpretation.) These Regulations amend the Medicinal Products (Prescription and Control of Supply) Regulations
- The purpose of these Regulations is to update the schedule of medicinal products which may be supplied and administered pursuant to Regulation 4F of the Medicinal Products (Prescription and Control of Supply) Regulations
- These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) Regulations
- Privacy Statement Accessibility European Legislation Identifier (PDF) Open Data License Ráiteas Príobháideachais Inrochtaineacht Aitheantóir Eorpach Reachtaíochta (ELI) Ceadúnas Sonraí Oscailte Liosta Fianán © Government of Ireland. Oireachtas Copyright Material is reproduced with the permission of the Houses of the Oireachtas © Rialtas na hÉireann. Atáirgtear ábhar faoi Chóipcheart le cead ó Thithe an Oireachtais